Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
By: GlobeNewswire - 03 Apr 2024 | Back to overview list |
|
RESEARCH TRIANGLE PARK, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees stock options to purchase an aggregate of 43,975 shares, and restricted stock units (RSUs) covering an aggregate of 30,625 shares, of BioCryst common stock. The options and RSUs were granted as of March 29, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $5.08 per share, which is equal to the closing price of BioCryst common stock on March 28, 2024, the last trading date prior to the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant. About BioCryst Pharmaceuticals BCRXW Contact: |
||
|
||
Copyright 2024 GlobeNewswire | Back to overview list |